论文部分内容阅读
在英国,肺癌是癌肿死亡的主要原因。改善肺癌的治疗需要有效的新药的开发。当前,技术的发展及对癌肿的生物学的充分认识,可以鉴定特殊的靶分子,根据靶点来设计新的药物。一、小细胞肺癌 (一) 新药的评价小细胞肺癌是实质性肿瘤中对化疗最敏感的肿瘤之一,化疗后多数病人肿瘤缩小又很快复发,关键问题是对多种药物产生了耐药。在英国有报告使用碳铂治疗未经化疗病人,有效率为60％;对已化疗病人有效率仅为19％。表明在未化疗病人试用新药,否决临床有效药物的可
In the United Kingdom, lung cancer is the leading cause of cancer deaths. The improvement of the treatment of lung cancer requires the development of effective new drugs. At present, the development of technology and the full understanding of the biology of cancer can identify specific target molecules and design new drugs based on the targets. First, small cell lung cancer (a) Evaluation of new drugs Small cell lung cancer is one of the most sensitive tumors for chemotherapy in solid tumors. After chemotherapy, most patients shrink and relapse quickly. The key problem is the resistance to multiple drugs. . In the United Kingdom, there have been reports of the use of carboplatin for the treatment of non-chemotherapy patients, with an effective rate of 60%; the effective rate for patients who have been treated with chemotherapy is only 19%. Shows that trials of new drugs in non-chemotherapy patients can reject clinically effective drugs